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Abstract Tripeptides of the general X-SO2-D-Ser-AA-
Arg-CO-Y formula, where X = a-tolyl, p-tolyl, 2,4,6-tri-
isopropylphenyl; AA = alanine, glycine, norvaline and
Y = OH, NH-(CH2)5NH2 were obtained and tested for
their effect on the amidolytic activities of urokinase,
thrombin, trypsin, plasmin, t-PA and kallikrein. The most
active compound towards urokinase was PhCH2SO2-D-Ser-
Gly-Arg-OH with Ki value 5.4 lM and the most active
compound toward thrombin was PhCH2SO2-D-Ser-NVa-
Arg-OH with Ki value 0.82 lM. The peptides were nontoxic
against porcine erythrocytes in vitro. PhCH2SO2-D-Ser-
Gly-Arg-OH showed cytotoxic effect against DLD cell
lines with IC50 values of 5 lM. For the highly selective
determination of the interaction of some of the synthesised
acids of tripeptides with urokinase and plasmin the Surface
Plasmon Resonance Imaging sensor has been applied.
These compounds bind to urokinase and plasmin in
0.05 mM concentration.
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Introduction
The proteolytic degradation of the extracellular matrix is
essential for the processes of tissue remodelling. These
processes take place in a number of distinct physiological
events in the healthy organism such as matrix degradation,
cell motility, angiogenesis and wound healing, as well as in
the critical mechanisms in tumor invasion and metastasis.
The plasminogen activation system has an important role
as a proteolytic cascade in these degradation reactions
(Irigoyen et al. 1999). The enzymatic system consists of
urokinase receptor (uPAR), urokinase plasminogen acti-
vator (uPA) and plasminogen activator inhibitors: type-1
(PAI-1) and type-2 (PAI-2). uPAR is a cell membrane-
anchored binding protein. uPA accumulates plasminogen
activation activity at cell surfaces (Ossowski and Aguirre-
Ghiso 2000). uPA is the primary cellular activator which
converts the pro-enzyme plasminogen into its active form
plasmin (Irigoyen et al. 1999). Plasmin is a broad spectrum
serine protease which dissolve fibrin blood clots, activates
metalloproteinases, degrades basement membrane and
many blood plasma proteins (Longstaff and Thelwell
2005).
Numerous studies have shown the relationship between
the level of expression of the uPA enzyme system and the
poor prognosis in brain, colon, stomach, ovary, breast and
kidney cancers (Duffy 2004; Sidenius and Blasi 2003; Dass
et al. 2008). Urokinase has become an attractive therapeutic
target in a variety of tumor.
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Urokinase inhibitors are divided into 3 classes: inhibitors
of the uPA–uPAR interaction, inhibitors of the uPA–PAI-1
interaction and inhibitors of uPA proteolytic activity.
uPA–uPAR interaction cyclic or linear inhibitors are
based on a specific amino acid sequence which comes from
the growth factor domain (GFD) of urokinase. These
peptides contains from 10 to 32 amino acids from this
region of uPA (Ploug et al. 2001; Goodson et al. 1994).
Corvas has described several substituted phenylpropi-
onic acid derivatives as effective PAI-1 antagonists
(Tamura et al. 2000). High levels of PAI-1 have been
suggested as one of the factors that contribute a poor
prognosis for cancer patients (Binder and Mihaly 2008).
Many small molecules have been reported to inhibit the
proteolytic activity of uPA. These peptide-based com-
pounds include the central aromatic or heteroaromatic
(thiophen, indole, pyridine) core (Klinghofer et al. 2001;
Schweinitz et al. 2004; Rockway and Giranda 2003). The
ring is substituted for a basic moiety, either an amidine or a
guanidine, which is essential to form a salt bridge with
Asp189 of uPA.
The number of reports concerning peptides as urokinase
inhibitors is limited. N-a-p-toluenesulphonyl-L-arginine
methyl ester, e-aminocaproic acid and its derivatives or
natural leupeptin and its derivatives are known as inhibi-
tors of urokinase (Rockway et al. 2002; Aoyagi et al.
1969). Glu-Gly-Arg-CH2Cl is a synthetic inhibitor which
inhibits urokinase with Ki value 5 lM and alkylates the
active-site histidine of urokinase (Lijnen et al. 1987). But
the most active peptide uPA inhibitor is phenethylsulfonyl-
D-Ser-Ala-Arg-H with IC50 value of 3.1 nM (Tamura et al.
2000).
On the basis of structure–activity literature data, we have
recently designed a series of peptide analogs as urokinase
inhibitors. The first series was H(Ac)-D-Ser-Ala-(Gly)-Arg-
OH(NH2) (Markowska et al. 2008) and the most active
inhibitor of urokinase was H-D-Ser-Gly-Arg-OH with an
IC50 value of 1 mM. The second series of peptide analogs of
arginine we synthesized were the peptides of the general
formula H-D-Ser-Ala-Arg-NH-X (Markowska et al. 2010),
where X = (CH2)n-NH2, n = 2–9, (CH2)m–OH, m = 2–4.
H-D-Ser-Ala-Arg-NH-(CH2)5-NH2 inhibited urokinase with
a Ki value of 6.3 lM. The third series of compounds with
D-Ser-Ala-Arg sequence were N-sulfonylamides peptides
(Markowska et al. 2010). 2,4,6-triisopropylphenyl-SO2-D-
Ser-Ala-Arg-OH was the most selective inhibitor of uroki-
nase and a-tolyl-SO2-D-Ser-Ala-Arg-OH was the most
active inhibitor of uPA with a Ki value of 24 lM.
We inserted aliphatic amino acid in the other group of
synthesised peptides in P2, and the most active compound
towards urokinase was H-D-Ser-NVa-Arg-OH with a Ki
value 0.85 lM (Markowska et al. 2011). Afterwards, we
synthesised peptides with non-code aromatic and cyclic
amino acid in P2 (Markowska et al. 2012) but this class of
peptides was not the inhibitors of urokinase.
The purpose of this paper was the synthesis and exam-
ination of the amidolytic activity of 17 novel peptides
against urokinase, thrombin, trypsin, plasmin, t-PA and
kallikrein. The peptides had the general X-SO2-NH-D-
Ser-AA-Arg-OH(NH-(CH2)5-NH2) formula, where X =
a-tolyl, p-tolyl, 2,4,6-triisopropylphenyl and AA = Ala,
Gly, NVa (Table 1.). We tested the hemolytic activity of
the peptides against porcine erythrocytes and the antitumor
activity against the following human cancer cells: colo-
rectal adenocarcinoma tumor DLD, standard MCF-7 and
estrogen-independent MDA-MB-231. We also examined
the interaction of some of the synthesised acids of tripep-
tides with urokinase and plasmin through a Surface
Plasmon Resonance Imaging (SPRI).
Experimental
Reagents
Fmoc-Arg(Pbf)-OH (Fmoc = 9-fluorenylmethyloxycarbonyl,
Pbf = pentamethyldihydrobenzofuran), chloranil, acetalde-
hyde, HOBt = 1-hydroxybenzotriazole, Fmoc-L-NVa-OH,
Fmoc-L-Ala-OH, Fmoc-Gly-OH, TNBS = 2,4,6-trinitroben
zenesulfonic acid (1 % solution in DMF), methanesulfonyl
chloride, a-toluenesulfonyl chloride and 2,4,6-triisopro-
pylbenzenesulfonyl chloride were purchased from Fluka
(Schnelldorf, Germany). Fmoc-D-Ser(t-Bu)-OH (t-Bu =
t-butyl) and 2-chlorotrityl chloride resin were purchased from
Merck (Novabiochem, Darmstadt, Germany). TFA = trifluo-
roacetic acid, DIPEA = diisopropylethylamine, DIC = diiso-
propylcarbodiimide, piperidine, TBTU = tetrafluoroborate
salt of the O-(benzotriazol-1-yl)-N,N,N0,N0-tetramethyluroni-
um tetrafluoroborate, NMP = 1-methyl-2-pyrrolidone and
1,5-diaminopentanetrityl resin were obtained from Iris Biotech
GmbH (Marktrewitz, Germany). DCM = dichloromethane,
DMF = dimethyl-formamide and methanol were the products
of Chempur (Piekary Slaskie, Poland). DCM was used without
further purification. DMF was distillated over ninhydrin and
stored under molecular sieves 4A. HPLC solvent acetonitrile
was purchased from Merck (Darmstadt, Germany). Urokinase,
trypsin, kallikrein and Bzl-L-Arg-pNA.HCl (Bzl = benzyl)
were purchased from Sigma (Schnelldorf, Germany). Plasmin,
S-2444 (pyro-Glu-Gly-Arg-pNA.HCl), S-2238 (H-D-Phe-Pip-
Arg-pNA), S-2251 (H-D-Val-Leu-Lys-pNA), S-2266 (H-D-
Val-Leu-Arg-pNA.2HCl and S-2288 (H-D-Ile-Pro-Arg-pNA)
were obtained from Chromogenix (Milano, Italy). Ac-Leu-
Leu-Arg-H, cysteamine hydrochloride, N-(2-hydroxyethyl)
piperazine-N0-(2-ethanesulfuric acid) (HEPES), N-ethyl-N0-
(3-dimethylaminopropyl) carbodiimide (EDC) were purchased
from Sigma (Steinheim, Germany). N-Hydroxysuccinimide
192 Int J Pept Res Ther (2013) 19:191–198
123
(NHS) was obtained from Aldrich (Munich, Germany).
Thrombin and phosphate buffered saline (PBS) were purchased
from Lubelska Wytwo´rnia Szczepionek (Lublin, Poland). t-PA
was obtained from Boehringer Ingelheim GmbH (Ingelheim,
Germany). HBS-ES solution pH 7.4 (0.01 M HEPES, 0.15 M
sodium chloride, 0.005 % Tween 20, 3 mM EDTA), acetic
buffer pH 3.79–5.57, phosphate buffer pH 7.17–8.04, carbon-
ate buffer pH 8.50–9.86 (Biomed, Lublin, Poland), photopo-
limer ELPEMER SD 2054, hydrophobic protective paint SD
2368 UV SG-DG (Peters, Kempen, Germany) were used as
received. Aqueous solutions were prepared with MilliQ water
(Simplicity MILLIPORE).
Peptide Synthesis
The peptides shown in Table 1 were synthesized manually
using the standard Fmoc-based strategy (Chan and White
2000). The Fmoc-Arg(Pbf)–OH was loaded on to the
2-chlorotrityl chloride resin with 2 M excess of DIPEA in
DCM and in the case of 1,5-diaminopentane trityl resin
using a molar ratio of amino acid/DIC/HOBt/resin 3:3:3:1
in DMF/NMP/DCM (1:1:1). Fmoc deprotection steps were
carried out with 20 % (v/v) piperidine in DMF/NMP (1:1)
for 15 min. The coupling reactions of Fmoc amino acids
were performed in DMF/NMP/DCM (1:1:1) using a molar
ratio of amino acid/DIC/HOBt/resin 3:3:3:1. In the case of
the coupling of Fmoc-D-Ser(t-Bu)-OH molar ratio of amino
acid/TBTU/HOBt/DIPEA/resin was 2:2:2:4:1. The sulfo-
nyl chlorides were used as 5 M excess to resin and were
dissolved in DCM with 10 M excess of DIPEA. The
reactions were monitored with the Steward chloranil test
(Vojkovski 1995) and with the TNBS test (Hancock and
Battersby 1976). The cleavage from the resin was carried
out with TFA/water (95/5). After 2.5 h stirring, the resin
was filtered and washed with TFA. The combined filtrates
were concentrated under reduced pressure. The crude
peptide was precipitated and washed with cold diethyl
ether, filtered, dissolved in water and lyophilized.
The Shimadzu LC-10A system (Shimadzu Europa GmbH,
Duisburg, Germany) was used for analytical and semipre-
paratory HPLC (Phenomenex C18, Jupiter 90A, 4 micron,
250 9 10 mm; Phenomenex C18, Jupiter 300A, 5 micron,
250 9 4 mm; solvents: A, 0.1 % aqueous TFA; B, 0.1 %
TFA in acetonitrile, gradient 0 % B to 100 % B in A in
30 min, flow rate 1 ml/min, monitored at 220 nm). The major
peak fraction was pooled and lyophilized. The molecular
weight determination was performed by mass spectrometry
using a Bruker Daltonics Esquire 6000 (Bruker Daltonik
GmbH, Leipzig, Germany) with electrospray ionization
(ESI), (Table 1).
Enzymatic Investigations
Determination of amidolytic activity was performed as
previously described (Okada et al. 1988). The detailed
description of the method is given below. The buffer and
the enzyme solution included:
Table 1 Analytical data of the synthesized compounds
No. Compound Yield (%) MW [M ? H]? Retention time (min)
1 PhCH2SO2-D-Ser-Ala-Arg-NH-(CH2)5-NH2 47.3 570.7 571.8 13.36
2 2,4,6-TriiPrPhSO2-D-Ser-Ala-Arg-NH-(CH2)5-NH2 56.3 682.9 684.3 20.07
3 CH3PhSO2-D-Ser-Ala-Arg-NH-(CH2)5-NH2 54.6 494.6 495.3 13.99
4 PhCH2SO2-D-Ser-Gly-Arg-NH-(CH2)5-NH2 55.8 556.6 557.5 13.16
5 2,4,6-TriiPrPhSO2-D-Ser-Gly-Arg-NH-(CH2)5-NH2 49.7 668.8 669.6 21.23
6 CH3PhSO2-D-Ser-Gly-Arg-NH-(CH2)5-NH2 61.2 480.5 481.4 13.46
7 PhCH2SO2-D-Ser-NVa-Arg-NH-(CH2)5-NH2 56.7 598.7 599.9 14.08
8 2,4,6-TriiPrPhSO2-D-Ser-NVa-Arg-NH-(CH2)5-NH2 58.5 710.9 711.8 20.81
9 CH3PhSO2-D-Ser-NVa-Arg-NH-(CH2)5-NH2 59.7 522.6 523.5 14.94
10 PhCH2SO2-D-Ser-Gly-Arg-OH 53.5 472.5 473.5 13.59
11 2,4,6-TriiPrPhSO2-D-Ser-Gly-Arg-OH 56.7 584.7 585.8 21.24
12 CH3PhSO2-D-Ser-Gly-Arg-OH 55.7 396.4 397.5 22.70
13 PhCH2SO2-D-Ser-NVa-Arg-OH 54.6 514.6 515.7 15.33
14 2,4,6-TriiPrPhSO2-D-Ser-NVa-Arg-OH 63.1 626.8 627.6 22.87
15 CH3PhSO2-D-Ser-NVa-Arg-OH 52.1 438.5 439.4 16.17
16 H-D-Ser-NVa-Arg-NH-(CH2)5-NH2 62.4 444.5 445.9 8.57
17 H-D-Ser-Gly-Arg-NH-(CH2)5-NH2 63.2 402.5 403.9 8.74
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(a) tris buffer—0.6 ml (pH 8.8),
enzyme: urokinase (50 U/ml),
synthetic substrate: S-2444 (0.1 ml, 3 mM);
(b) tris buffer—0.5 ml (pH 8.4),
enzyme: thrombin (1 U/ml),
synthetic substrate: S-2238 (0.2 ml, 0.75 mM);
(c) tris buffer—0.5 ml (pH 7.4),
enzyme: plasmin (0.4 U/ml),
synthetic substrate: S-2251 (0.2 ml, 3 mM);
(d) borane buffer—0.5 ml (pH 7.5),
enzyme: trypsin (0.4 U/ml),
synthetic substrate: Bzl-L-Arg-pNA.HCl
(0.2 ml, 8 mM);
(e) tris buffer—0.6 ml (pH 9.0),
enzyme: kallikrein (3 U/ml),
synthetic substrate: S-2266 (0.1 ml, 7.5 mM);
(f) tris buffer—0.6 ml (pH 8.4),
enzyme: t-PA (1.67 mg/ml),
synthetic substrate: S-2288 (0.1 ml, 10 mM).
Buffer and 0.1 ml of enzyme solution was added to
0.2 ml of examined compound dissolved in 0.15 M NaCl
(1–17) (as control 0.15 M NaCl). The mixture was incu-
bated for 3 min at 37 C, then the synthetic substrate was
added. After 20 min of incubation, the reaction was stop-
ped by adding 0.1 ml of 50 % acetic acid, and the absor-
bance of the released p-nitroaniline was measured at
405 nm (Spekol 1300, AnalyticJena). Every value repre-
sents the average of the triplicate determination. IC50 value
was considered as the concentration of the inhibitor, which
decreased the absorbance at 405 nm by 50 %, compared
with the absorbance measured under the same conditions
without the inhibitor. Ki was calculated from IC50 based on
Cheng–Prusoff equation (Cheng and Prusoff 1973). The
results are given in Table 2.
Our results were compared with the data obtained for
Ac-Leu-Leu-Arg-H and Ac-Leu-Leu-Arg-COCHO (leupep-
tin—natural, microbial origin, inhibitor of proteinases and
analog of leupeptin, respectively (Aoyagi et al. 1969)).
Antitumor Activity
Tissue Culture
All studies were performed on MCF-7, MDA-MB-231 and
DLD cells lines were purchased from American Type
Culture Collection (Rockville, USA). The cells were
maintained in DMEM supplemented with 5 % fetal bovine
serum (FBS), 2 mmol/ml glutamine, 50 U/ml penicillin,
50 mg/ml streptomycin at 37 C in a 5 % CO2 incubator.
Cytotoxicity Assay
The toxicity of the evaluated peptides was determined by
the method of Plumb et al. (1989) in 10, 100, 250, 500 and
1,000 lM concentrations. MCF-7, MDA-MB-231 and
DLD cells were maintained as described above. After 48 h
of incubation of the cells with synthesized peptides, the
medium was discarded and the cells were rinsed three
times with phosphate buffered saline (PBS). The cells were
then incubated for 4 h in 2 ml of PBS with 50 ml of MTT
(5 mg/ml). After removal of the medium, the cells were
lysed in 200 ml of DMSO with 20 ml of Sorensen’s buffer
(0.1 M glycine with 0.1 M NaCl, pH 10.5). The absor-
bance was measured at 570 nm. The cytotoxic activity of
synthesized peptides was calculated as percentage of non-
viable cells and the IC50 value was estimated from loga-
rithm curves as shown in Table 3.
Hemolytic Activity
Pig’s fresh red blood cells (p-RBC) were washed three
times with PBS (35 M phosphate buffer/0.15 mM NaCl,
pH 7.4) and were centrifugated at 1,000g for 10 min to
remove plasma and the buffy coat. The various concen-
trations of peptides (100, 250, 500 and 1,000 lg/ml) were
incubated with the erythrocyte suspension for 1 h at 37 C
(the final erythrocyte concentration was 5 % v/v). After the
centrifugation (1,000g for 10 min), 100 ll of the super-
natant was transferred into sterilized 96-well plates, where
hemoglobin release was monitored with the use of the
Infinite M200 plate reader (TECAN, Salzburg, Austria) by
measuring the absorbance at 414 nm. Zero hemolysis
(blank), hemolysis with Ac-Leu-Leu-Arg-H as reference
compound for synthesised peptides and 100 % hemolysis
which consisted of p-RBC suspended in PBS and 0.1 %
Triton-X-100 were determined respectively. The percent-
age of hemolysis was calculated with the following for-
mula: hemolysis (%) = (Abs414 nm in the peptide solution
in PBS/Abs414nm in 0.1 % Triton-X-100 in PBS) 9 100.
SPRI Investigation
Chip Preparation
Gold chips were manufactured as described in previous
papers (Gorodkiewicz 2009; Gorodkiewicz and Regulska
2010; Gorodkiewicz et al. 2011). The gold surface of the chip
was covered with photopolymer and hydrophobic paint.
9 9 12 free gold surfaces were obtained. Using this chip,
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nine different solutions can be simultaneously measured
without mixing the tested solutions. Twelve single SPRI
measurements can be performed from one solution.
Inhibitor Immobilization
Chips were rinsed with ethanol and water and dried under a
stream of nitrogen. They were then immersed in 20 mM
cysteamine ethanolic solutions for at least 2 h. The chips
were then rinsed with ethanol and water and dried under a
stream of nitrogen.
Among the synthesised compounds, four were selected
for the examination of the interaction between the enzyme
and the inhibitor. They were acids of peptides 10, 12, 13 and
14. Acids can be bound to a gold surface via cysteamine. A
series of concentrations 0.002, 0.005, 0.01, 0.02, 0.05, 0.1
and 0.2 mM was used for each peptide. The concentration of
the enzymes was constant 1 ng/ml. Inhibitor solution, acti-
vated with NHS (50 mM) and EDC (200 mM) was placed on
the cysteamine-modified surface, and incubated at 37 C for
1 h (Gorodkiewicz 2009; Gorodkiewicz and Regulska 2010;
Gorodkiewicz et al. 2011). The chip was then treated with
the urokinase or plasmin solution for 10 min, rinsed with
Table 2 Inhibition of H-D-Ser-AA-Arg-OH on the amidolytic activity of enzymes






1 n.i. 2.0 ± 0.16 n.i.
2 n.i. 90.9 ± 7.27 n.i.
3 n.i. 68.2 ± 5.45 n.i.
4 n.i. 58.2 ± 4.65 n.i.
5 44.6 ± 3.57 56.4 ± 4.51 n.i.
6 n.i. 46.4 ± 3.71 n.i.
7 n.i. 111.8 ± 8.95 n.i.
8 n.i. 52.7 ± 4.22 n.i.
9 n.i. 89.1 ± 7.13 n.i.
10 5.4 ± 0.43 102.7 ± 8.22 0.97 ± 0.08
11 15.8 ± 1.27 89.1 ± 7.13 n.i.
12 11.2 ± 0.89 10.0 ± 0.8 n.i.
13 n.i. 13.6 ± 1.09 0.82 ± 0.06
14 9.5 ± 0.76 120.0 ± 9.60 n.i.
15 n.i. 167.2 ± 13.38 n.i.
16 n.i. 137.3 ± 10.98 n.i.
17 n.i. 139.1 ± 11.13 n.i.
Ac-Leu-Leu-Arg-H (leupeptin) IC50 = 42 lg/ml (Kawada and Umezawa 1995)
n.i. (Saino et al. 1988)
IC50 = 5.8 lg/ml (Kawada and Umezawa 1995)
IC50 = 10
-5 M (Saino et al. 1988)
–
Ac-Leu-Leu-Arg-COCHO – 4.9 lM (Lynas et al. 2001) –
n.i. No cytotoxic effect was observed in maximum concentration (20 mM). The examined compound did not influence the enzymatic activity of trypsin,
kallikrein and t-PA in maximum concentration (20 mM)
Table 3 The nonviability of MDA cells treated for 24 h with
different concentrations of the synthesised peptides
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HBS–ES buffer and dried. Finally, the SPRI measurement
was performed. Each solution was put on two measuring
fields (each consisting of 12 measuring points); thus 24
replicates were done in each case. The results are given in
Figs. 1 and 2.
SPRI Measurements
SPRI measurements with an application of an enzyme
array were performed as described in previous papers
(Gorodkiewicz 2009; Gorodkiewicz and Regulska 2010;
Gorodkiewicz et al. 2011). Briefly, the measurements were
performed at a fixed angle of incident light and the
reflectivity was simultaneously measured across an entire
chip surface. The contrast values obtained for all pixels
across a particular sample single spot were integrated. Thus
the SPRI signal was integrated over the single spot area.
Background correction was applied. NIH ImageJ version
1.42 software was used to evaluate the SPRI images in 2D
form. The signal was measured twice on the basis of reg-
istered images, after immobilisation of enzymes and then
after interaction inhibitors. The SPRI signal, which is
proportional to coupled enzymes, was obtained from sub-
traction between the signal before and after interaction with
enzymes for each spot separately.
Results and Discussion
Inhibition of the Serine Proteases
The examined compound did not influence the enzymatic
activity of trypsin, kallikrein and t-PA.
We expected that the use of the specific tripeptide
sequence towards urokinase (D-Ser-AA-Arg) would cause
some selectivity (Ke et al. 1997). According to the obtained
results, only five compounds inhibited urokinase activity but
none of them were selective. The most active inhibitor of
u-PA was 10 PhCH2-SO2-D-Ser-Gly-Arg-OH with Ki value
5.4 lM. H-D-Ser-Gly-Arg-OH and H-D-Ser-Ala-Arg-OH
were previously examined (Markowska et al. 2008) and they
were the most active inhibitors of urokinase with IC50 value
of 1 mM and 2 mM respectively (Ki = 90 lM and 180 lM,
author’s unpublished data). In 2010 we synthesised N-sul-
fonylamide peptides with alanine as P2 (Markowska et al.
2010). a-Tolyl- and p-tolylsulfonylamides of the examined
tripeptides were active towards urokinase. The compound
2,4,6-triisopropylphenylsulfonyl-D-Ser-Ala-Arg-OH was
the most selective and we chose 2,4,6-triisopropylphe-
nylsulfonyl fragment to the present research. In current work
only compound 14 2,4,6-triiPrPhSO2-D-Ser-NVa-Arg-OH
had some activity towards urokinase, but in this case it was
not selective. Only amide of arginine 5 2,4,6-triiPrPhSO2-
D-Ser-NVa-Arg-NH-(CH2)5-NH2 were active urokinase
inhibitors with Ki value 44.6 lM.
All of the synthesised peptides were inhibitors of plasmin.
The compound 1 PhCH2SO2-D-Ser-Ala-Arg-NH-(CH2)5-
NH2 was the most active plasmin inhibitor with Ki value of
2 lM in this series of peptides. Compound 1 contains a
fragment of pentamethylenediamine (cadaverine) as amide
arginine residue in its structure which seems to have sig-
nificant influence on the activity and selectivity. The moiety
of cadaverine is the form of decarboxylated derivative of
lysine. In literature, there are peptides with C-terminus lysine
amide and also amide residue of lysine substituted with
cadaverine, as inhibitors of plasmin (Markowska et al. 2007;
Midura-Nowaczek et al. 2006). This kind of compounds was
designed to be similar to natural substrate sequence hydro-
lysed by plasmin.
The most active inhibitors of thrombin in whole series of















Fig. 1 Dependence of SPRI signal (a.u.) of urokinase-inhibitor


















Fig. 2 Dependence of SPRI signal (a.u.) of plasmin-inhibitor com-
plex on inhibitor concentration. Plasmin concentration 1 ng/ml
196 Int J Pept Res Ther (2013) 19:191–198
123
PhCH2SO2-D-Ser-NVa-Arg-OH with Ki value 0.97 and
0.82 lM.
Antitumor Activity of Synthesised Peptides
The examined compounds did not influence MCF-7 cancer
cells. It was found that the proteolytic activity of uPA is
closely connected with cell-surface events at the breast
cancer cell. MCF-7 has low uPAR/uPA-expressing and
low plasminogen-binding, whereas MDA-MB-231 has
high uPAR/uPA-expressing and high plasminogen-binding
(Stillfried et al. 2007). Thus, the influence of the synthe-
sized compounds on the cytotoxic effect of MCF-7 cells
could be insignificant.
The peptides 1–17 and the examined natural inhibitor of
proteinases leupeptin were comparably cytotoxic to MDA-
MB-231. The most interesting peptide was compound 10
with an IC50 values of 5 lM for DLD cells, which was the
most active inhibitor of urokinase in the amidolytic test.
Hemolytic Activity
The results indicated that the concentration up to 1,000 lg/ml
of the synthesized peptides did not lyse porcine erythrocytes.
The Effect of Newly Synthesised Inhibitor
Concentration on the SPRI Signals of Plasmin
and Urokinase
The first aim of this investigation was the qualitative
studies of the interaction between the potential inhibitor
and the enzyme. The second aim was to find an optimal
inhibitor concentration for the interaction with the enzymes.
The positive SPRI signal was obtained for urokinase
after the interaction with inhibitors 10 and 14, as well as for
plasmin with inhibitors 12 and 13. The obtained curves for
compounds 10, 12, 13 and 14 were a Langmuir isotherm
type, with the plateau of the signal above 0.02 mM. Leu-
peptin was used as a reference inhibitor for plasmin and
urokinase. The newly synthesised inhibitors act in a similar
way as leupeptin.
Conclusion
The most active compound towards urokinase was PhCH2
SO2-D-Ser-Gly-Arg-OH with Ki value 5.4 lM and the most
active compound toward thrombin was PhCH2SO2-D-
Ser-NVa-Arg-OH with Ki value 0.82 lM. The peptides were
nontoxic against porcine erythrocytes in vitro. PhCH2SO2-D-
Ser-Gly-Arg-OH compound showed cytotoxic effect against
DLD cell lines with IC50 values of 5 lM. Some of the syn-
thesised compounds bind to urokinase and plasmin in
0.05 mM concentration evaluated by the Surface Plasmon
Resonance Imaging (SPRI) sensor.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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